Mechanism of the antiproliferative action of leflunomide. A77 1726, the active metabolite of leflunomide, does not block T-cell receptor-mediated signal transduction but its antiproliferative effects are antagonized by pyrimidine nucleosides.

@article{Cao1995MechanismOT,
  title={Mechanism of the antiproliferative action of leflunomide. A77 1726, the active metabolite of leflunomide, does not block T-cell receptor-mediated signal transduction but its antiproliferative effects are antagonized by pyrimidine nucleosides.},
  author={Wenhong Cao and Peter N Kao and Allen C Chao and Phyllis Gardner and Josephine W M Ng and Randall E. Morris},
  journal={The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation},
  year={1995},
  volume={14 6 Pt 1},
  pages={1016-30}
}
BACKGROUND Leflunomide, a novel immunosuppressive drug, prolongs experimental graft survival effectively and has been well tolerated in patients with rheumatoid arthritis. A77 1726, the active metabolite of leflunomide, inhibits lymphocyte proliferation in vitro. This study was conducted in Jurkat T cells to investigate the effects of A77 1726 on signal transduction pathways initiated by ligands of the T-cell receptor CD3 complex and to evaluate the effects of A77 1726 on nucleotide… CONTINUE READING